Skip to content

A Global Meta-analysis of the Prevalence of HIV, Hepatitis C Virus, and Hepatitis B Virus Among People Who Inject Drugs—Do Gender-Based Differences Vary by Country-Level Indicators?

Research output: Contribution to journalArticle

Original languageEnglish
Article numberjiz058
Number of pages13
JournalJournal of Infectious Diseases
Early online date6 Feb 2019
DOIs
DateAccepted/In press - 2 Feb 2019
DateE-pub ahead of print (current) - 6 Feb 2019

Abstract

Background: Women-specific factors exist that increases vulnerability to drug-related harms from injecting drug use including bloodborne viruses (BBV), but gender differences in BBV prevalence have not been systematically examined.

Methods: We conducted meta-analyses to estimate country, regional, and global prevalence of serologically-confirmed HIV, hepatitis C (anti-HCV) and hepatitis B (HBsAg) prevalence in people who inject drugs (PWID) by gender. Gender differences in BBV (relative risks, RR in women vs men) were regressed on country-level prevalence and inequality measures.

Results: Gender differences varied by countries and regions. HIV prevalence was higher among women than men in Sub-Saharan Africa (RR=2.8, 95%CI 1.8-4.4) and South Asia (RR=1.7, 1.1-2.7); anti-HCV was lower among women in the Middle East and North Africa (RR=0.6, 0.5-0.7) and East and Southeast Asia (RR=0.8, 0.7-0.9). Gender differences varied with country-levels of BBV in the general population, human development, and income distribution.

Conclusion: HIV infection was more prevalent in women who inject drugs compared to their male counterparts in some countries, but there is between and within regional variation. In countries where women are at higher risks, there is a need to develop gender-sensitive harm reduction services for the particularly marginalized population of women who inject drugs.

    Research areas

  • HIV, hepatitis b, hepatitis c antibodies, gender, viruses, drug usage, gender differences, women who inject drugs, injecting drug use, substance use, intravenous, HIV seroprevalence, HBV, HCV, hepatitis, blood-borne virus, blood born pathogens

Documents

Documents

  • Full-text PDF (accepted author manuscript)

    Rights statement: This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Oxford University Press at https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiz058/5307802. Please refer to any applicable terms of use of the publisher.

    Accepted author manuscript, 882 KB, PDF-document

    Embargo ends: 6/02/20

    Request copy

DOI

View research connections

Related faculties, schools or groups